The Wockhardt Group, formerly a prominent player in the pharmaceutical industry, is facing monumental difficulties. With mounting debts and a struggling business, the group's valuable assets are now being put up for grabs. This dramatic turn of events has sent shockwaves through the industry, raising eyebrows among analysts. It remains unknown who